Literature DB >> 26493505

Uric Acid Is a Risk Indicator for Metabolic Syndrome-related Colorectal Adenoma: Results in a Korean Population Receiving Screening Colonoscopy.

Hyo Jin Kim1, Jee Eun Kim2, Ji Hye Jung1, Eun Ran Kim1, Sung Noh Hong1, Dong Kyung Chang1, Hee Jung Son1,2, Poong Lyul Rhee1, Jae J Kim1, Young Ho Kim1.   

Abstract

BACKGROUND/AIMS: An association between serum uric acid and cancer risk has been noted over the past few decades. There is ongoing debate about whether hyperuricemia represents an independent risk factor for colorectal neoplasm. We investigated the association between serum uric acid and prevalence of colorectal adenoma considering numerous confounding factors.
METHODS: A cross-sectional study was performed with individuals who underwent a routine health check-up examination, including a screening colonoscopy and blood chemistry. The association between serum uric acid and prevalence of colorectal adenoma was estimated from the results of a logistic regression analysis.
RESULTS: Of the 1,066 participants, 402 had colorectal adenoma (37.7%). In univariate models, the prevalence of colorectal adenoma was higher in participants in the fourth quartile uric acid level, compared to those in the first quartile uric acid level (OR, 1.67; 95% CI, 1.17-2.42; p=0.004). However, no significant association was detected between serum uric acid and prevalence of colorectal adenoma in multiple logistic regression analysis. A number of metabolic syndrome components exhibited a strong association with the prevalence of colorectal adenoma in the multivariate model (OR, 3.46 for highest vs. lowest; 95% CI, 1.30-9.20; p=0.021). Moreover, serum uric acid was strongly associated with metabolic syndrome-associated variables, including waist circumference, fasting blood glucose, systolic blood pressure, diastolic blood pressure, triglyceride, and high-density lipoprotein.
CONCLUSIONS: Uric acid is not an independent risk factor for colorectal adenoma but is a risk indicator for metabolic syndrome-related colorectal adenoma.

Entities:  

Keywords:  Colorectal neoplasms; Metabolic syndrome X; Uric acid

Mesh:

Substances:

Year:  2015        PMID: 26493505     DOI: 10.4166/kjg.2015.66.4.202

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  5 in total

1.  Relationship between serum uric acid and metastatic and nonmetastatic rectal cancer patients with undergoing no chemotherapy.

Authors:  Cheng Yuan; Xin-Hua Xu; Xiao-Long Wang; Lu Xu; Zhuo Chen; Yuan-Qiang Li
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

2.  Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX.

Authors:  Xi Zhang; Qing-Hong Chen; Ying Yang; Jing-Xin Lin; Yan-Chun Li; Tian-Yu Zhong; Jie Chen; Si-Qi Wu; Xiao-Hu Chen; Rui-Si Zhou; Jia-Man Lin; Dong-Qing Wang; Qiu-Xing He; Yan-Ting You; Xing-Hong Zhou; Qiang Zuo; Yan-Yan Liu; Jing-Ru Cheng; Yi-Fen Wu; Xiao-Shan Zhao
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

3.  Comparison of some biochemical markers between early-onset and late-onset colorectal precancerous lesions: A single-center retrospective study.

Authors:  Chao-Tao Tang; Jun Li; Zhenzhen Yang; Chunyan Zeng; Youxiang Chen
Journal:  J Clin Lab Anal       Date:  2022-08-16       Impact factor: 3.124

4.  The relationship between serum uric acid and colorectal cancer: a prospective cohort study.

Authors:  Wenqiang Li; Tong Liu; Sarah Tan Siyin; Qingsong Zhang; Yiming Wang; Liying Cao; Jun Qu
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

5.  Hyperuricaemic UrahPlt2/Plt2 mice show altered T cell proliferation and defective tumor immunity after local immunotherapy with Poly I:C.

Authors:  Camille Baey; Jianping Yang; Franca Ronchese; Jacquie L Harper
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.